New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future
Open Access
- 15 May 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 205 (suppl_2), S241-S249
- https://doi.org/10.1093/infdis/jis034
Abstract
For the first time in 40 years, a portfolio of promising new compounds for the treatment of tuberculosis is on the horizon. The introduction of new drugs in combination treatment for all forms of tuberculosis raises several issues related to patients’ access to novel treatments, programmatic feasibility, cost effectiveness, and implications for monitoring and surveillance, particularly with regard to the development of drug resistance. Particular attention should be given to the identification of optimal drug combination(s) for the treatment of all forms of tuberculosis, particularly in high-risk and vulnerable groups, such as human immunodeficiency virus–coinfected persons and children, and to the rational use of new drugs. Addressing these issues adequately requires the establishment of clear guidelines to assist countries in the development of policies for the proper use of tuberculosis drugs in a way that guarantees access to best treatments for all those in need and avoids inappropriate use of new drugs. After a description of these various challenges, we present activities that will be carried out by the World Health Organization in collaboration with key stakeholders for the development of policy guidelines for optimal treatment of tuberculosis.Keywords
This publication has 35 references indexed in Scilit:
- Faculty Opinions recommendation of A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.Published by H1 Connect ,2012
- Three Months of Rifapentine and Isoniazid for Latent Tuberculosis InfectionThe New England Journal of Medicine, 2011
- Global tuberculosis drug development pipeline: the need and the realityThe Lancet, 2010
- New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmesCurrent Opinion in Pulmonary Medicine, 2010
- Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2009
- The Diarylquinoline TMC207 for Multidrug-Resistant TuberculosisThe New England Journal of Medicine, 2009
- Design issues in pivotal drug trials for drug sensitive tuberculosis (TB)Tuberculosis, 2008
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLoS Medicine, 2006
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005
- Oxazolidinone antibioticsThe Lancet, 2001